A Phase II study of Cisplatin and Pemetrexed for Advanced Non-Small(Non squamous cell)Lung Cancer

A Phase II study of Cisplatin and Pemetrexed for Advanced Non-Small(Non squamous cell)Lung Cancer - A Phase II study of Cisplatin and Pemetrexed for Advanced Non-Small(Non squamous cell)Lung Cancer

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000002847

Enrollment

Registered

2009-12-04

Start date

2009-11-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Advanced Non-Small Cell (Non squamous cell)lung Cancer

Interventions

Cisplatin 75mg/m2 iv pemetrexed 500mg/m2 iv

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Histologically or Cytologoically confirmed NSCLC (non squamous cell).

Exclusion criteria

Exclusion criteria: A recognized ILD or pulmonary fibrosis on X-rays.

Design outcomes

Primary

Measure	Time frame
ORR	—

Secondary

Measure	Time frame
toxicity,PFS,OS	—

Countries

Japan

Contacts

Public ContactFumiyoshi Ohyanagi

Japanese Foundation for cancer research Thoracic Medical oncology , Thoracic Center

03-3520-0111

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026